Skip to content
The African Exponent DATA
Resources

Review pending. Every figure has been located on its cited source page in an AI-assisted source verification (matched to the document's text) (9 October 2026). Independent review has not yet been carried out, and these pages are not indexed.AI-assisted source check done; independent review pending; not indexed. About the review

Presco

PRESCO · Nigerian Exchange · Consolidated statements

On this page
Company details
Legal name
Presco Plc
Listing
PRESCO on the Nigerian Exchange, active · ISIN NGPRESCO0005 (observed 2026-10-08)
Sector
Not classified (our classification from the stated principal activity)
Financial year ends
31 December

Overview

Year ended 31 December 2025 · annual report, signed / final · source

  • Revenue

    NGN 331 billion

    330,639,543 NGN thousands · p26

    +59.3% vs 2024

  • Operating profit / (loss)

    NGN 215 billion

    214,950,390 NGN thousands · p26

    +70.9% vs 2024

  • Profit / (loss) for the year

    NGN 121 billion

    121,354,087 NGN thousands · p26

    +56.0% vs 2024

  • Total assets

    NGN 926 billion

    926,008,472 NGN thousands · p27

    +94.9% vs 2024

  • Total equity

    NGN 443 billion

    442,749,446 NGN thousands · p27

    +109.7% vs 2024

  • Cash from operations

    NGN 70.0 billion

    70,019,868 NGN thousands · p30

    −21.9% vs 2024

Large amounts are rounded for reading (NGN million / billion / trillion); exact figures as printed are under each amount and in the tables. No currency conversion.

Financial statements

Exact figures as printed. Each column comes from one filing; labels are as printed in the newest filing. Amounts in NGN thousands unless the row says otherwise; brackets are negative.

† from a supplementary filing for the same year · ‡ signed audited statements preferred over a disputed figure · “–” is a printed dash, explained below the table

Column sources

  • FY2025 — annual report, signed / final; reported for the year · source
  • FY2024 — annual report, signed / final; comparative in the FY2025 filing · source

Income statement

Income statement, NGN thousands. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filing
Revenue 330,639,543 207,504,191
Cost of sales (88,459,846) (65,527,830)
Gross profit 242,179,697 141,976,361
Administrative expenses (58,017,222) (38,504,374)
Selling and distribution expenses (4,428,660) (3,114,324)
Other gains1 288,467 51,360
Other operating income 7,771,712 3,922,631
Gain on foreign exchange transactions 5,785,604 5,469,342
Fair value gains on biological assets2 21,745,368 28,999,279
Impairment loss on trade and other receivables (374,576) (329,744)
Loss on Monetary Position3 –4 (12,673,574)
Operating profit before finance cost and finance income 214,950,390 125,796,957
Finance cost (44,823,074) (12,792,168)
Interest income calculated under the effective interest method 7,851,900 218,490
Profit before tax 177,979,216 113,223,279
Tax expense (56,625,129) (35,430,193)
Profit for the year 121,354,087 77,793,086
Non-controlling interest5 –6 1,724,150
Other comprehensive income, net of tax 39,500,700 6,702,663
Total comprehensive income for the year 160,854,787 84,495,749
  1. Printed “-”, read as nil: subtotal_arithmetic: is.operating_profit.
  2. Printed “-”; reading unresolved, so no amount is shown. Printed dash; no printed subtotal confirms a nil reading.
Notes and alternative reported figures (4)
  1. “Other gains” is an issuer-specific line, not mapped to a shared definition: Other gains (note 11), printed apart from other operating income.
  2. “Fair value gains on biological assets” is an issuer-specific line, not mapped to a shared definition: Fair value gains on biological assets (note 18a).
  3. “Loss on Monetary Position” is an issuer-specific line, not mapped to a shared definition: IAS 29 hyperinflation net monetary loss (2025 printed '-').
  4. “Non-controlling interest” is an issuer-specific line, not mapped to a shared definition: Share of profit attributable to non-controlling interest.

Balance sheet

Balance sheet, NGN thousands. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filing
Goodwill1 59,314,408 26,713,999
Intangible assets 44,392 93,453
Property, plant and equipment 386,674,462 273,735,042
Right-of-use assets –2 3,800,850
Total non-current assets 446,033,262 304,343,344
Biological assets3 128,341,304 70,505,131
Inventories 40,078,518 30,747,412
Trade and other receivables 48,979,962 38,097,747
Cash and cash equivalents 262,575,426 31,402,555
Total current assets 479,975,210 170,752,845
Total assets 926,008,472 475,096,189
Share capital 583,333 500,000
Share premium 235,895,100 1,173,528
Other reserves (16,657,302) (1,358,019)
Foreign Exchange reserves4 46,844,917 6,394,235
Retained earnings 176,083,398 126,729,311
Equity attributable to owners 442,749,446 133,439,055
Non-Controlling Interests –5 77,745,546
Total equity 442,749,446 211,184,601
Defined benefit obligations 6,171,745 1,655,199
Borrowings 299,970,537 46,544,013
Deferred income6 2,144,691 347,213
Lease liabilities 2,243,561 3,698,240
Deferred tax liabilities 57,701,861 34,618,045
Total non-current liabilities 368,232,395 86,862,710
Borrowings 17,326,663 8,902,484
Bank overdraft 116,721 2,918,466
Deferred income7 679,961 1,269,974
Defined benefit obligations8 2,052,667 2,201,412
Lease liabilities 84,784 165,588
Current tax liabilities 32,548,589 25,863,658
Trade and other payables 62,217,246 135,727,296
Total current liabilities 115,026,631 177,048,878
Total liabilities 483,259,026 263,911,588
Total equity and liabilities 926,008,472 475,096,189
  1. Printed “-”, read as nil: subtotal_arithmetic: bs.non_current_assets.
  2. Printed “-”, read as nil: subtotal_arithmetic: bs.total_equity.
Notes and alternative reported figures (6)
  1. “Goodwill” is an issuer-specific line, not mapped to a shared definition: Goodwill (note 16).
  2. “Biological assets” is an issuer-specific line, not mapped to a shared definition: Biological assets (note 18), presented within current assets.
  3. “Foreign Exchange reserves” is an issuer-specific line, not mapped to a shared definition: Foreign currency translation reserve.
  4. “Deferred income” is an issuer-specific line, not mapped to a shared definition: Non-current deferred income (government grants, note 29.1).
  5. “Deferred income” is an issuer-specific line, not mapped to a shared definition: Current deferred income (government grants, note 29.1).
  6. “Defined benefit obligations” is an issuer-specific line, not mapped to a shared definition: Current portion of defined benefit obligations (note 26).

Cash flow

Cash flow, NGN thousands. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filing
Cash generated in operating activities 101,901,110 103,058,796
Benefits paid1 (2,201,412) (1,141,066)
Income taxes paid (29,679,830) (12,237,193)
Net cash generated in operating activities 70,019,868 89,680,537
Acquisition of property, plant and equipment (64,344,181) (33,298,720)
Proceeds from sale of property, plant and equipment 275,827 69,238
Acquisition of subsidiary, net of cash acquired2 –3 9,191,435
Interest received 7,851,900 218,490
Net cash used in investing activities (56,216,454) (23,819,557)
Proceeds from loans and borrowings 111,626,114 3,477,076
Principal repayment on borrowings (26,399,054) (8,723,792)
Proceeds from issue of share capital4 234,804,905 –5
Dividends paid (72,000,000) (24,300,000)
Dividend paid to Non-controlling Interest6 –5 (7,304,996)
Unclaimed dividend invested7 (172,727) –5
Interest repayments on lease liabilities (549,100) (295,254)
Interest repayments on borrowings (24,426,623) (7,607,027)
Principal repayment on lease liabilties (1,971,943) (602,353)
Net cash generated from/(used in) financing activities 220,911,572 (45,356,346)
Net increase in Cash and cash equivalents 234,714,985 20,504,633
Cash and cash equivalents as at beginning of year 28,484,089 5,469,344
Effect of movement in exchange rate on cash held (740,370) 2,510,112
Cash and Cash Equivalents at end of year 262,458,705 28,484,089
  1. Printed “-”, read as nil: subtotal_arithmetic: cf.cash_from_investing.
  2. Printed “-”, read as nil: subtotal_arithmetic: cf.cash_from_financing.
Notes and alternative reported figures (5)
  1. “Benefits paid” is an issuer-specific line, not mapped to a shared definition: Employee benefits paid (note 26.2), operating activities.
  2. “Acquisition of subsidiary, net of cash acquired” is an issuer-specific line, not mapped to a shared definition: Investing activities (2025 printed '-').
  3. “Proceeds from issue of share capital” is an issuer-specific line, not mapped to a shared definition: Financing activities (2024 printed '-').
  4. “Dividend paid to Non-controlling Interest” is an issuer-specific line, not mapped to a shared definition: Financing activities (2025 printed '-').
  5. “Unclaimed dividend invested” is an issuer-specific line, not mapped to a shared definition: Financing activities (2024 printed '-').

Per share and shares

Per share and shares. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filing
Earnings / (loss) per share (per share)3 120.64671 76.06892
Profit / (loss) attributable to shareholders (NGN thousands)4 121,354,087 76,068,936
  1. Printed as 12,064.67 Kobo; value converted to NGN at 100 Kobo = 1 NGN.
  2. Printed as 7,606.89 Kobo; value converted to NGN at 100 Kobo = 1 NGN.
Notes and alternative reported figures (2)
  1. Earnings / (loss) per share: printed as “Basic (Kobo)”.
  2. Profit / (loss) attributable to shareholders: printed as “Owners of the parent”.

Segments

Segment data not yet collected for this company in the pilot.

Dividends

Proposed or recommended, declared and paid are different events and are kept apart. A statement that no dividend was proposed does not mean none was paid.

Dividend events, the issuer's wording, and amounts as printed
Year endedEventWording as printedAmountUnitSource
31 Dec 2025 Dividends paid (cash flow statement) Dividends paid (72,000,000) NGN thousands Annual report, p30
31 Dec 2024 Dividends paid (cash flow statement) Dividends paid (24,300,000) NGN thousands Annual report, p30

Sources

Each filing used on this page, newest period first. Dates are the document's own; the date we retrieved a file is shown separately and is never a publication date.

  • PRESCO PLC Annual report, consolidated and separate financial statements For the year ended 31 December 2025

    Year ended 31 December 2025 · Annual report · signed / final

    Audit: KPMG Professional Services (Chartered Accountants), Lagos, unmodified opinion · signed

    Auditor's sign-off: Adegoke A. Oyelami, FCA, for KPMG Professional Services

    Final status: Independent auditor's report to the shareholders of Presco Plc on the consolidated and separate financial statements (PDF pp21-25; opinion p21), unmodified, 'Signed:' by hand above 'Adegoke A. Oyelami, FCA, FRC/2012/PRO/ICAN/004/00000000444, For: KPMG Professional Services, Chartered Accountants, 30 April 2026, Lagos, Nigeria', with the ICAN seal (p25, page image). The printed page states the statements were 'approved and authorised for issue by the Board of Directors on 29 April 2026' with handwritten signatures of Olakanmi Rasheed Sarumi (Chairman), Reji George (Managing Director) and Johnson Amandor (Chief Financial Officer) (p27, page image).

    Document date
    30 Apr 2026
    Auditor's report
    30 Apr 2026
    Board approval
    29 Apr 2026
    Retrieved by us
    8 Oct 2026 (not a publication date)
    Used for
    statement columns FY2025, FY2024
    Basis
    consolidated statements · NGN thousands (printed “N'000”)
    • Cash and cash equivalents at the end of the year in the cash-flow statement (262,458,705; 2024: 28,484,089, p30) are net of the bank overdraft (balance sheet 262,575,426 less 116,721; 2024: 31,402,555 less 2,918,466, p27).
    • HIDDEN TEXT-LAYER DATE DIFFERS FROM THE PRINTED PAGE: the text layer of p27 holds an approval sentence reading 'approved and authorised for issue by the Board of Directors on 2 April 2026' (with stray signatory names), while the printed page reads '29 April 2026' (page image). The board approval date is recorded as printed (29 April 2026). No hidden figure differing from the printed statements was found on pp26, 27 or 30 (figures compared with the renders).
    • Key audit matter: valuation of biological assets (pp22-23). The auditor also reports an unmodified limited-assurance conclusion on internal control over financial reporting (pp19-20, 25). 2024 includes an IAS 29 loss on monetary position (12,673,574) and non-controlling interests (77,745,546) that are nil in 2025.
    • Earnings per share is printed in kobo (Basic 12,064.67; 2024: 7,606.89; diluted printed identically, p26); stored in naira with the printed figure and unit kept.
    Technical details
    File
    119 pages, with a text layer
    SHA-256
    c3a6b54ee53e16a8c47fae1076796d3cb2a9f523c99d107d1dc9d925d34bf3ec
    Entity as printed
    PRESCO PLC (the Company) and its subsidiaries (the Group)
    Exchange copy
    retrieved 2026-10-08T18:01:22Z

Data notes

No figure-level notes beyond those in the tables.

Review status: every figure has been located on its cited source page in an AI-assisted source verification (matched to the document's text) (9 October 2026). Independent review is pending for every figure; automated checks and the AI-assisted verification are not independent review.

Download

Figures shown on this page (CSV) — the same selected figures at their exact printed values, each with its source document, SHA-256, page, selection rule and reading. Independent review of these figures is pending.

· Company methodology and coverage